Nephropathy News and Research

RSS

Nephropathy is a broad medical term used to denote disease or damage of the kidney, which can eventually result in kidney failure. The primary and most obvious functions of the kidney are to excrete any waste products and to regulate the water and acid-base balance of the body – therefore loss of kidney function is a potentially fatal condition.

Study: Charcoal lessens atherosclerotic lesions in mice with kidney damage

Charcoal may provide a new approach to managing the high rate of heart disease in patients with advanced kidney disease, according to preliminary research being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.

2 Nov 2009

Amgen publishes Phase 3 study results of Aranesp

Amgen today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes.

31 Oct 2009

Shire announces third quarter 2009 financial results

Shire plc, the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009.

31 Oct 2009

Data from multiple clinical and preclinical studies evaluating Hematide announced

Affymax, Inc. and Takeda Pharmaceutical Global Research & Development Center, Inc., today announced data from multiple clinical and preclinical studies evaluating Hematide, including preliminary results of a Phase 2 trial which demonstrated that Hematide increased hemoglobin levels in a group of anemic hemodialysis (HD) patients.

31 Oct 2009

Young medical school graduates more likely to recommend kidney transplantation for CKD patients

Compared with veteran doctors, recent medical school graduates are more likely to refer chronic kidney disease (CKD) patients for kidney transplantation before their patients require dialysis, according to a paper being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.

30 Oct 2009

Pre-dialysis recipients with high kidney function do not benefit from kidney transplants

Pre-dialysis transplant recipients with a high level of kidney function don't benefit from their transplant more than pre-dialysis recipients with low level kidney function, according to a paper being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.

30 Oct 2009

Case Western Reserve awarded $14.7M to lead study on effects of lowering systolic blood pressure

Case Western Reserve University School of Medicine has received a $14.7 million, nine-year contract from the National Institutes of Health to be one of five institutions to lead a trial to determine if lowering systolic blood pressure in hypertensive patients, without diabetes, to below the currently recommended level can reduce the incidence of cardiovascular and kidney disease and slow cognitive decline.

30 Oct 2009

NIH awards $75 million to establish medical research consortium to combat health disparities

The National Institutes of Health has awarded $75 million to Charles Drew University of Medicine and Science and three other historically black institutions to establish a medical research consortium to combat health disparities in minority and underserved populations.

30 Oct 2009

Group education is an effective way to help alleviate organ shortage and increase living donations

Get-togethers with a kidney disease patient's family and friends can improve their willingness to consider donation, according to a paper being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.

30 Oct 2009

Reading levels of kidney transplant consent forms can make it difficult for patients to make informed decisions

Kidney transplant consent forms are often written at a level that makes it difficult for many kidney patients to fully understand them, according to a paper being presented at the American Society of Nephrology's annual meeting in San Diego, CA. The study findings indicate that consent forms are written on average at a 12th-grade reading level, but to ensure all patients fully comprehend treatment options should be prepared at a 5th - 8th grade reading level.

30 Oct 2009

Anabolic steroids may cause severe kidney dysfunction

Athletes who use anabolic steroids may gain muscle mass and strength, but they can also destroy their kidney function, according to a paper being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.

30 Oct 2009

Dynavax Technologies announces first clinical data for HEPLISAV investigational hepatitis B vaccine

Dynavax Technologies Corporation today announced the first clinical data for HEPLISAVTM investigational hepatitis B vaccine in chronic kidney disease patients.

30 Oct 2009

NIH launches randomized trail to determine whether lower BP goal cuts the risk of heart and kidney diseases

The National Institutes of Health is launching a large multicenter randomized clinical trial to determine whether maintaining blood pressure levels lower than current recommendations further reduces the risk of cardiovascular and kidney diseases, or age-related cognitive decline.

30 Oct 2009

Vitamin D deficiency may account for increased risk of end-stage renal disease in African Americans

Low levels of vitamin D may account for nearly 60 percent of the elevated risk of end-stage renal disease (ESRD) in African Americans, according to a report in the December Journal of the American Society of Nephrology (JASN).

30 Oct 2009

Unaudited consolidated financial results for the third-quarter reported by AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2009.

29 Oct 2009

Noncardiovascular mortality are rates higher in patients receiving dialysis

Compared to the general population, patients starting dialysis have an increased risk of death that is not attributable to a higher rate of death from cardiovascular causes, as previously thought, according to a study in the October 28 issue of JAMA.

28 Oct 2009

Shire receives European approval for FOSRENOL

Shire plc, the global specialty biopharmaceutical company, today announced it has received approval through the European Mutual Recognition Procedure for an extension to the current indication for FOSRENOL(R) (lanthanum carbonate), paving the way to make the non-calcium, non-resin phosphate binder available throughout the EU to control hyperphosphataemia in chronic kidney disease (CKD) patients who are not on dialysis with a serum phosphorus level greather than or equal to 1.78mmol/L (5.5mg/dL).

28 Oct 2009

Protein crucial for insulin regulation may play a role in diabetes

A cellular protein from a family involved in several human diseases is crucial for the proper production and release of insulin, new research has found, suggesting that the protein might play a role in diabetes.

27 Oct 2009

Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals

Napo Pharmaceuticals, Inc. has in-licensed from the University of California Regents additional small-molecule cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor technology including gastrointestinal (GI) and polycystic kidney disease (PKD) indications.

26 Oct 2009

Japanese Patent granted for Pharmalink AB's Nefecon

Pharmalink AB announced today that it has been granted Japanese Patent No 4326696, "Methods and means for treating glomerulonephritis" for its product Nefecon(R) which is being developed to treat IgA nephropathy, a glomerulonephritis leading to end-stage renal disease (ESRD). Counterparts of the patent have been issued for other territories including the EU, US and China.

26 Oct 2009

Nephropathy News and Research

Further Reading

Study: Charcoal lessens atherosclerotic lesions in mice with kidney damage

Amgen publishes Phase 3 study results of Aranesp

Shire announces third quarter 2009 financial results

Data from multiple clinical and preclinical studies evaluating Hematide announced

Young medical school graduates more likely to recommend kidney transplantation for CKD patients

Pre-dialysis recipients with high kidney function do not benefit from kidney transplants

Case Western Reserve awarded $14.7M to lead study on effects of lowering systolic blood pressure

NIH awards $75 million to establish medical research consortium to combat health disparities

Group education is an effective way to help alleviate organ shortage and increase living donations

Reading levels of kidney transplant consent forms can make it difficult for patients to make informed decisions

Anabolic steroids may cause severe kidney dysfunction

Dynavax Technologies announces first clinical data for HEPLISAV investigational hepatitis B vaccine

NIH launches randomized trail to determine whether lower BP goal cuts the risk of heart and kidney diseases

Vitamin D deficiency may account for increased risk of end-stage renal disease in African Americans

Unaudited consolidated financial results for the third-quarter reported by AMAG Pharmaceuticals

Noncardiovascular mortality are rates higher in patients receiving dialysis

Shire receives European approval for FOSRENOL

Protein crucial for insulin regulation may play a role in diabetes

Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals

Japanese Patent granted for Pharmalink AB's Nefecon

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News